PILL:NYE-Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (USD)

ETF | Trading--Leveraged Equity |

Last Closing

USD 9.07

Change

-0.47 (-4.93)%

Market Cap

N/A

Volume

0.01M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-14 )

Largest Industry Peers for Trading--Leveraged Equity

Symbol Name Price(Change) Market Cap
SOXL Direxion Daily Semiconductor B..

-0.09 (-0.30%)

USD 11.50B
QLD ProShares Ultra QQQ

-1.58 (-1.44%)

USD 7.95B
FNGU MicroSectors FANG+ Index 3X Le..

-9.06 (-1.72%)

USD 5.90B
SSO ProShares Ultra S&P500

-1.28 (-1.32%)

USD 5.68B
UPRO ProShares UltraPro S&P500

-1.87 (-1.96%)

USD 4.34B
TECL Direxion Daily Technology Bull..

-1.38 (-1.43%)

USD 3.15B
YINN Direxion Daily FTSE China Bull..

-0.89 (-3.16%)

USD 2.02B
USD ProShares Ultra Semiconductors

-0.11 (-0.16%)

USD 1.40B
LABU Direxion Daily S&P Biotech Bul..

-11.66 (-8.98%)

USD 0.99B
DPST Direxion Daily Regional Banks ..

-2.44 (-1.66%)

USD 0.88B

ETFs Containing PILL

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Leveraged Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.03% 44% F 69% C-
Dividend Return 1.01% 52% F 17% F
Total Return 18.04% 44% F 66% D+
Trailing 12 Months  
Capital Gain 74.76% 70% C- 94% A
Dividend Return 2.24% 63% D 31% F
Total Return 76.99% 70% C- 94% A
Trailing 5 Years  
Capital Gain -42.04% 29% F 11% F
Dividend Return 1.79% 31% F 5% F
Total Return -40.25% 27% F 9% A-
Average Annual (5 Year Horizon)  
Capital Gain 50.74% 78% C+ 94% A
Dividend Return 51.24% 78% C+ 93% A
Total Return 0.49% 38% F 12% F
Risk Return Profile  
Volatility (Standard Deviation) 368.36% 15% F 3% F
Risk Adjusted Return 13.91% 28% F 32% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.